CLINICAL TRIALS PROFILE FOR EFLORNITHINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Eflornithine Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003076 ↗ | Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus | Completed | National Cancer Institute (NCI) | Phase 2 | 1995-10-01 | RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus. |
| NCT00003076 ↗ | Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus | Completed | University of Michigan Cancer Center | Phase 2 | 1995-10-01 | RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus. |
| NCT00003076 ↗ | Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus | Completed | University of Michigan Rogel Cancer Center | Phase 2 | 1995-10-01 | RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus. |
| NCT00003814 ↗ | Eflornithine in Treating Patients With Bladder Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer. |
| NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | Chao Family Comprehensive Cancer Center | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Eflornithine Hydrochloride
Condition Name
Clinical Trial Locations for Eflornithine Hydrochloride
Trials by Country
Clinical Trial Progress for Eflornithine Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Eflornithine Hydrochloride
Sponsor Name
